Innovation Pharmaceuticals IncOOTC IPIX Stock Report

Innovation Pharmaceuticals, Inc. is a clinical stage biotechnology company. The company is headquartered in Wakefield, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2007-04-02. The firm is in the business of developing small molecule therapies to treat diseases with medical need, particularly in the areas of inflammatory diseases, cancer, dermatology and anti-infectives. The firm is primarily focused on the advancement of Brilacidin in Oral Mucositis and in infectious diseases. Brilacidin is Company’s lead drug candidate in Host Defense Protein (HDP)-mimetic franchise. Brilacidin is a de novo-designed synthetic, non-peptidic, small molecule that kills pathogens swiftly, greatly reducing the likelihood of drug resistance developing. The company also functions in a robust immunomodulatory capacity, lessening inflammation and promoting healing. Its ongoing activities include Brilacidin drug manufacturing, scientific report writing, and supportive research activities.